Hematologic Oncology

Naval G. Daver, MD, reviews the safety and efficacy of quizartinib in relapsed/refractory acute myeloid leukemia as seen in the phase 3 QuANTUM-R study.

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

Experts in leukemia comment on the utilization of FLT3 inhibitors in combination with chemotherapy in early and recurrent acute myeloid leukemia.

AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.

Hematologist-oncologists review the typical presentation and diagnosis of acute and chronic GVHD and define how severity is classified.

Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, provide insight on the nature of graft-vs-host disease (GVHD) and common risk factors for acute and chronic GVHD.

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

The combination of the selective MCL-1 inhibitor AMG 176 plus gilteritinib was found to synergistically target preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.

A panel of experts recall the challenges of accurate early detection of transplant-associated thrombotic microangiopathy and its importance for improved patient outcomes.

Amit K. Verma, MD, spotlights new agents that have entered the myelodysplastic syndrome treatment arsenal and novel combinations currently under exploration, as well as efforts that are showing promise in patients with acute myeloid leukemia.

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.

Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.